CAB LA PrEP Cohort study is an observational study which aims to gather information about individuals who use CAB (Cabotegravir) LA (Long-Acting) injections as PrEP (Pre-Exposure Prophylaxis) to prevent contraction of HIV. It aims to collect information about the individuals who are initiating CAP LA PrEP to assess the usage patterns, adherence, effectiveness, safety and resistance in practice.  

The study objectives are to:
1) Describe the population initiating CAB LA for PrEP, including proportion of individuals who use oral lead in (OLI) and proportion of those with direct to injection (DTI)
2) Monitor for adherence by assessing the frequency of delayed and missed injections without oral PrEP
3) Monitor for incidence of HIV diagnosis while on CAB for PrEP and describe the timing of incident HIV diagnoses relative to timing of CAB PrEP usage
4) Monitor for occurrence of drug induced liver injury (DILI) and hypersensitivity reaction (HSR) following CAB LA injections
5) Evaluate incidence of and risk for developing resistance among individuals with an HIV diagnosis while on CAB LA for PrEP

MAIN FUNDING BODY